2017
DOI: 10.1101/cshperspect.a031252
|View full text |Cite
|
Sign up to set email alerts
|

The Biology of Bone Metastasis

Abstract: Summary Bone metastasis, or the development of secondary tumors within the bone of cancer patients, is a debilitating and incurable disease. Despite its morbidity, the biology of bone metastasis represents one of the most complex and intriguing of all oncogenic processes. This complexity derives from the intricately organized bone microenvironment in which the various stages of hematopoiesis, osteogenesis, and osteolysis are jointly regulated but spatially restricted. Disseminated tumor cells (DTCs) from vario… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
110
0
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 126 publications
(111 citation statements)
references
References 125 publications
0
110
0
1
Order By: Relevance
“…The osteoclastic bone resorption is significant to make the skeleton a permissive environment in most bone metastases 60 . Osteoclasts, the only cells capable of bone resorption, derived from myeloid lineage, were reported to be controlled by RANKL, PTHrP and Jagged 1 61‐64 . In a recent report, LIGHT (tumour necrosis factor superfamily member 14, TNFSF14), derived from monocytes, was shown to promote osteolysis in NSCLC bone metastases and could be a new therapy target 65 .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The osteoclastic bone resorption is significant to make the skeleton a permissive environment in most bone metastases 60 . Osteoclasts, the only cells capable of bone resorption, derived from myeloid lineage, were reported to be controlled by RANKL, PTHrP and Jagged 1 61‐64 . In a recent report, LIGHT (tumour necrosis factor superfamily member 14, TNFSF14), derived from monocytes, was shown to promote osteolysis in NSCLC bone metastases and could be a new therapy target 65 .…”
Section: Discussionmentioning
confidence: 99%
“…In a recent report, LIGHT (tumour necrosis factor superfamily member 14, TNFSF14), derived from monocytes, was shown to promote osteolysis in NSCLC bone metastases and could be a new therapy target 65 . RANKL can be secreted by osteoblast lineages or stromal cells, and PTHrp can be derived from tumour cells 61,66‐68 . Although PTHrP and RANKL have been reported to be associated with NSCLC bone metastasis, 69,70 therapy efficiency of treatment targeting RANKL on NSCLC bone metastases is extremely limited.…”
Section: Discussionmentioning
confidence: 99%
“…First, the bone-metastatic potential may depend on host factors that determine the BM metastasis niche (e.g., cellular and secreted components of the local environment, such as bone stromal cells, osteoblasts, osteoclasts, immune cells, growth factors, cyto-and chemokines, etc.). These niche factors have been shown to control seeding, dormancy, and outgrowth of BM metastases [32]. During in vitro cultivation, the niche factors are absent so that the gene expression profile of BM metastasis cells may revert to that of the primary tumor cells.…”
Section: Discussionmentioning
confidence: 99%
“…Hal tersebut menggambarkan bahwa tulang berperan tidak hanya menjadi target namun juga sebagai sumber radiasi yang memaparkan radiasi kepada sumsum merah yang merupakan sumsum tulang. Dalam proses metastasis, sumsum merah juga berperan mengumpulkan sel-sel tumor dari hampir semua jenis kanker, dan metastasis tulang terbentuk di hematopoietik sumsum merah aktif [23]. Dan dari Izotop (summary product characteristic) [24], dosimetri 99m Tc-MDP produksi Institute of Isotope.Co.Ltd.…”
Section: Hasil Dan Pembahasanunclassified